ALVO logo

ALVO Alvotech

NASDAQ Global Market · Drug Manufacturers - Specialty & Generic · Healthcare

$4.19
-0.48 (-10.28%)

Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to add…

Market Cap: $1.50Bwww.alvotech.com

Price

No data yet.

Social Signal Score

45
5d
—
30d
52
3 mentions
—
60d
41
7 mentions
—
90d
42
10 mentions
—
news: 10

Analyst Ratings

5 analysts
Buyconsensus
Strong Buy 0Buy 3Hold 2Sell 0Strong Sell 0
Avg price target$8.33+98.8%
Low $8Median $8High $9
Current Consensus

Revenue

$111.40M+1296.05%
$0.00$66.25M$132.50M$198.75M
Mar 2019Sep 2026

Analyst Estimates

FY2025
$-0.08
$-0.19–$0.03
3 analysts
FY2026
$-0.08
$-0.25–$0.08
3 analysts
FY2027
$0.25
$0.21–$0.29
4 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Lisa Graver
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1,279
Beta
0.18
Country
LU
Piotroski score
1 / 9 (Weak)
Altman Z-score
-1.37
www.alvotech.com